1. The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancerErik Škof, Sebastjan Merlo, Gašper Pilko, Borut Kobal, 2016, original scientific article Abstract: Primary treatment of patients with advanced epithelial ovarian cancer consists of chemotherapy either before (neoadjuvant chemotherapy, NACT) or after primary surgery (adjuvant chemotherapy). The goal of primary treatment is no residual disease after surgery (R0 resection) what is associated with an improvement in survival of patients. There is, however, no evidence of survival benefits in patients with R0 resections after prior NACT. Methods. We retrospectively reviewed the records of patients who were treated with diagnosis of epithelial ovarian cancer at Institute of Oncology Ljubljana in the years 2005%2007. The differences in the rates of R0 resections, progression free survival (PFS), overall survival (OS) and in five-year and eight-year survival rates between patients treated with NACT and patients who had primary surgery were compared. Results. Overall 160 patients had stage IIIC epithelial ovarian cancer. Eighty patients had NACT and eighty patients had primary surgery. Patients in NACT group had higher rates of R0 resection (42% vs. 20%; p = 0.011) than patients after primary surgery. PFS was 14.1 months in NACT group and 17.7 months after primary surgery (p = 0.213). OS was 24.8 months in NACT group and 31.6 months after primary surgery (p = 0.012). In patients with R0 resections five-year and eight-year survival rates were 20.6% and 17.6% in NACT group compared to 62.5% and 62.5% after primary surgery (p < 0.0001), respectively. Conclusions. Despite higher rates of R0 resections achieved by NACT, survival of patients treated with NACT was inferior to survival of patients who underwent primary surgery. NACT should only be offered to patients with advanced epithelial cancer who are not candidates for primary surgery.
Keywords: ovarian cancer, advanced ovarian cancer, neoadjuvant chemotherapy, primary surgery
Published in DiRROS: 30.04.2024; Views: 65; Downloads: 12
 Full text (597,52 KB) |
2. Mesenteric ischemia after capecitabine treatment in rectal cancer and resultant short bowel syndrome is not an absolute contraindication for radical oncological treatmentAna Perpar, Erik Brecelj, Nada Rotovnik-Kozjek, Franc Anderluh, Irena Oblak, Marija Skoblar Vidmar, Vaneja Velenik, 2015, short scientific article Abstract: Thrombotic events, arterial or venous in origin, still remain a source of substantial morbidity and mortality in cancer patients. The propensity for their development in oncology patients is partially a consequence of the disease itself and partially a result of our attempts to treat it. One of the rarest and deadliest thromboembolic complications is arterial mesenteric ischemia. The high mortality rate is caused by its rarity and by its non-specific clinical presentation, both of which make early diagnosis and treatment difficult. Hence, most diagnoses and treatments occur late in the course of the disease. The issue survivors of arterial mesenteric ischemia may face is short bowel syndrome, which has become a chronic condition after the introduction of parenteral nutrition at home. We present a 73-year-old rectal cancer patient who developed acute arterial mesenteric thrombosis at the beginning of the pre-operative radiochemotherapy. Almost the entire length of his small intestine, except for the proximal 50 cm of it, and the ascending colon had to be resected. After multiorgan failure his condition improved, and he was able to successfully complete radical treatment (preoperative radiotherapy and surgery) for the rectal carcinoma, despite developing short bowel syndrome (SBS) and being dependent upon home-based parenteral nutrition to fully cover his nutritional needs. Mesenteric ischemia and resultant short bowel syndrome are not absolute contraindications for radical oncological treatment since such patients can still achieve long-term remission.
Keywords: acute mesenteric ischemia, capecitabine, multiorgan failure, rectal cancer, short bowel syndrome
Published in DiRROS: 23.04.2024; Views: 53; Downloads: 23
Full text (557,53 KB) |
3. |
4. |
5. Experimental investigation of the shear force capacity of prismatic cross laminated timber beamsHenrik Danielsson, Tomaž Pazlar, Erik Serrano, Boris Azinović, 2024, original scientific article Abstract: Experimental tests of Cross Laminated Timber (CLT) under in-plane beam loading conditions are presented. The influence of the element layup, the individual lamination width, and the beam overhang at the supports on the shear force capacity was investigated. All the CLT beams had the same gross cross section, and a 4-point-bending test setup was used. The experimentally determined load-bearing capacities are compared with the load-bearing capacities resulting from analytical methods proposed for structural design, focusing on shear failure in the crossing areas of flatwise bonded laminations (shear failure mode III). The test results indicate no or very small influence of the element layup and the lamination width on the shear force capacity. These results partly contradict the predictions of the proposed design methods. Of the three studied beam geometry parameters, the beam overhang at the support had the greatest influence on the load-bearing capacity.
Keywords: cross laminated timber, CLT, beam, shear testing, shear capacity, design methods
Published in DiRROS: 15.04.2024; Views: 115; Downloads: 63
Full text (3,32 MB)
This document has many files! More... |
6. |
7. |
8. |
9. |
10. Apparatus for positron emission tomographyMarko Starič, Samo Korpar, Erik Margan, Marko Šifrar, Aleš Stanovnik, Nataša Budihna, Metka Milčinski, Boris Šket, 1998, original scientific article Published in DiRROS: 19.01.2024; Views: 171; Downloads: 42
Full text (693,52 KB) |
